Bortezomib induced subconjunctival hemorrhage

Navin Patil, Ommurugan Balaji, Karthik S. Udupa, Karthik Rao

Research output: Contribution to journalArticle

Abstract

Many drugs are used in the treatment of multiple myeloma but thalidomide, lenalidomide, bortezomib, and dexamethasone and their combination remain the main stay of treatment. The molecular formula of bortezomib is C19H25BN4O4 and its chemical name is (3-methyl-1-(3-phenyl-2-pyrazin-2-ylcarbonylamino-propanoyl) amino-butyl) boronic acid. Mechanisms by which it acts is usually by 26 SProteasome inhibition leading to degradation of anti-apoptotic proteins. Bortezomib is known to cause many side effects. Hence, we report a rare case of bortezomib-induced subconjunctival hemorrhage in our tertiary care hospital.

Original languageEnglish
Pages (from-to)10-11
Number of pages2
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume10
Issue number4
DOIs
Publication statusPublished - 01-04-2017

Fingerprint

Hemorrhage
Boronic Acids
Apoptosis Regulatory Proteins
Thalidomide
Tertiary Healthcare
Multiple Myeloma
Tertiary Care Centers
Dexamethasone
Names
Bortezomib
Pharmaceutical Preparations
lenalidomide

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{a6da4ccc5cd24e00b0f71f7602315f65,
title = "Bortezomib induced subconjunctival hemorrhage",
abstract = "Many drugs are used in the treatment of multiple myeloma but thalidomide, lenalidomide, bortezomib, and dexamethasone and their combination remain the main stay of treatment. The molecular formula of bortezomib is C19H25BN4O4 and its chemical name is (3-methyl-1-(3-phenyl-2-pyrazin-2-ylcarbonylamino-propanoyl) amino-butyl) boronic acid. Mechanisms by which it acts is usually by 26 SProteasome inhibition leading to degradation of anti-apoptotic proteins. Bortezomib is known to cause many side effects. Hence, we report a rare case of bortezomib-induced subconjunctival hemorrhage in our tertiary care hospital.",
author = "Navin Patil and Ommurugan Balaji and Udupa, {Karthik S.} and Karthik Rao",
year = "2017",
month = "4",
day = "1",
doi = "10.22159/ajpcr.2017.v10i4.16907",
language = "English",
volume = "10",
pages = "10--11",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "4",

}

Bortezomib induced subconjunctival hemorrhage. / Patil, Navin; Balaji, Ommurugan; Udupa, Karthik S.; Rao, Karthik.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, No. 4, 01.04.2017, p. 10-11.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bortezomib induced subconjunctival hemorrhage

AU - Patil, Navin

AU - Balaji, Ommurugan

AU - Udupa, Karthik S.

AU - Rao, Karthik

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Many drugs are used in the treatment of multiple myeloma but thalidomide, lenalidomide, bortezomib, and dexamethasone and their combination remain the main stay of treatment. The molecular formula of bortezomib is C19H25BN4O4 and its chemical name is (3-methyl-1-(3-phenyl-2-pyrazin-2-ylcarbonylamino-propanoyl) amino-butyl) boronic acid. Mechanisms by which it acts is usually by 26 SProteasome inhibition leading to degradation of anti-apoptotic proteins. Bortezomib is known to cause many side effects. Hence, we report a rare case of bortezomib-induced subconjunctival hemorrhage in our tertiary care hospital.

AB - Many drugs are used in the treatment of multiple myeloma but thalidomide, lenalidomide, bortezomib, and dexamethasone and their combination remain the main stay of treatment. The molecular formula of bortezomib is C19H25BN4O4 and its chemical name is (3-methyl-1-(3-phenyl-2-pyrazin-2-ylcarbonylamino-propanoyl) amino-butyl) boronic acid. Mechanisms by which it acts is usually by 26 SProteasome inhibition leading to degradation of anti-apoptotic proteins. Bortezomib is known to cause many side effects. Hence, we report a rare case of bortezomib-induced subconjunctival hemorrhage in our tertiary care hospital.

UR - http://www.scopus.com/inward/record.url?scp=85017134459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017134459&partnerID=8YFLogxK

U2 - 10.22159/ajpcr.2017.v10i4.16907

DO - 10.22159/ajpcr.2017.v10i4.16907

M3 - Article

AN - SCOPUS:85017134459

VL - 10

SP - 10

EP - 11

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 4

ER -